Corvus Pharmaceuticals

IPO

Pioneering ITK inhibition

Public · Burlingame, United States · Founded 2014 · $319.1M raised

Employees
11–50
Founded
2014
Business Model
B2B
Total Funding
$319.1M
Last Round
$150.0M Corporate RoundJan 2026
Rounds
5
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 6 funding rounds and 5 investors for this company. The full record is or through the API.

About

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies with the potential to significantly improve the treatment of immune diseases and cancer. The company's lead program, soquelitinib, is a first-in-class oral therapy that selectively inhibits ITK (interleukin-2-inducible T-cell kinase) to modulate and control parallel signaling pathways in the immune system. The founding team includes inventors and scientists behind Rituxan (rituximab), Imbruvica (ibrutinib), and Zelboraf (vemurafenib). ITK inhibition represents a novel approach to immune modulation that the company believes parallels the transformative impact of those landmark therapies in oncology and autoimmune disease.

Summary

Corvus Pharmaceuticals is a Biotech company based in Burlingame, United States, founded in 2014. It has raised $319.1M in total across 5 rounds, most recently a $150.0M Corporate Round in Jan 2026. Investors include OrbiMed, Rock Springs Capital and Adams Street Partners.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Corporate RoundCorporate Round2026 (est.)
$150.0M

Sign up to see all 6 events

Funding: Series A through Corporate Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Corvus Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/corvus-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/corvus-pharmaceuticals" alt="Corvus Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>